Lee's Pharmaceutical Holdings Limited logo

Lee's Pharmaceutical Holdings Limited (0950)

Market Closed
13 Aug, 08:00
HKEX HKEX
1. 10
HKD
+0.03
+2.8037%
HKD
1B Market Cap
- P/E Ratio
0.04% Div Yield
677,500 Volume
- Eps
1.07 HKD
Previous Close
Add Transaction
Day Range
1.07 1.1
Year Range
0.99 2.7
Want to track 0950 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0950 closed today higher at 1.1 HKD, an increase of 2.8037% from yesterday's close, completing a monthly increase of 6.7961% or 0.07 HKD. Over the past 12 months, 0950 stock lost -27.6316%.
0950 pays dividends to its shareholders, with the most recent payment made on Jun 15, 2026. The next estimated payment will be in In 4 months on Dec 15, 2026 for a total of 0.023 HKD.
The last earnings report, released on Mar 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

0950 Chart

People also search for

China Dongxiang Group Co Ltd.
0.31 HKD
-3.1746%
Sa Sa International Holdings Limited
0.92 HKD
-0.5405%
Associated International Hotels Limited
5.25 HKD
0%
BeijingWest Industries International Ltd.
4.74 HKD
+1.826%
China Boton Group Co. Ltd.
2.54 HKD
+0.3953%

Lee's Pharmaceutical Holdings Limited (0950) FAQ

What is the stock price today?

The current price is 1.10 HKD.

On which exchange is it traded?

Lee's Pharmaceutical Holdings Limited is listed on HKEX.

What is its stock symbol?

The ticker symbol is 0950.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.04%.

What is its market cap?

As of today, the market cap is 1B.

Has Lee's Pharmaceutical Holdings Limited ever had a stock split?

No, there has never been a stock split.

Lee's Pharmaceutical Holdings Limited Profile

Specialty Retail Industry
Consumer Discretionary Sector
- CEO
HKEX Exchange
KYG5438W1116 ISIN
Hong Kong Country
1,094 Employees
27 May 2026 Last Dividend
- Last Split
- IPO Date

Overview

Lee's Pharmaceutical Holdings Limited is a distinguished investment holding entity focused on the realm of pharmaceutical development, manufacturing, marketing, and distribution, mainly within the People's Republic of China. Founded in 1994 and anchored in Sha Tin, Hong Kong, this company prides itself on addressing a broad spectrum of health concerns through its innovative pharmaceutical solutions. Its commitment spans across various disease areas such as cardiovascular health, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. Operationally, Lee's Pharmaceutical bifurcates its offerings into two primary segments: Proprietary and Generic Products; and Licensed-In Products. Through these segments, the company offers a comprehensive range of pharmaceutical products, from self-developed and generic medications to licensed-in drugs, aimed at tackling a plethora of health conditions and contributing significantly to patient care and wellness.

Products and Services

The extensive product lineup of Lee's Pharmaceutical Holdings Limited is categorically divided to cater to varying health needs with precision and efficacy:

  • Nadroparin Calcium Injection and Livaracine: Targeting the prevention and treatment of blood clots and deep vein thrombosis.
  • Yallaferon: Aided in managing and combating viral infections.
  • Slounase: Geared towards promoting hemostasis.
  • Eyprotor: Formulated to aid in the healing of corneal ulcers.
  • Treprostinil Injection: Specially developed for the management of pulmonary arterial hypertension.
  • Fondaparinux Sodium Injection: Utilized in the treatment of deep vein thrombosis.
  • Sodium Phenylbutyrate Granules: Addressing urea cycle disorders through its therapeutic properties.
  • Carnitene: For addressing carnitine deficiency, ensuring proper metabolic functioning.
  • Sancuso: Providing relief from chemotherapy-induced nausea and vomiting, enhancing patient comfort during cancer treatment.
  • Bredinin, Centraxal Plus, Episil: Covering a range from immunosuppression management in renal transplantation to treating acute otitis media with tympanostomy tubes, and managing oral mucositis pain.
  • Gaslon N, Intrarosa, Adasuve: Encompassing treatments for gastric ulcer and gastritis, vulvovaginal atrophy, and agitation associated with schizophrenia or bipolar I disorder in adults, respectively.
  • Diverse Treatments in Hypertension, Pain Management, and More: Including medications like Zanidip, Rasilez for hypertension; Readyfusor for post-operative pain management; highlighting its extensive involvement in addressing myriad health concerns.
  • Treatments for Neurological and Psychiatric Conditions: Offering Teglutik for Amyotrophic lateral sclerosis and Trittico for insomnia/depression, illustrating Lee's Pharmaceutical's dedication to improving quality of life for patients with neurological and psychiatric conditions.
  • Unidrox, Dicoflor, and VSL#3: Ranging from treatment for urinary and respiratory tract infections to probiotic supplements for maintaining digestive health.

Contact Information

Address: Building 20E
Phone: 852 2314 1282